Grünenthal Stories

Grünenthal announced that the company has enrolled the first patient in its global clinical Phase III programme for resiniferatoxin (RTX).

RTX is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist, with a well-validated mechanism of action. The discovery of TRPV1 was awarded the Nobel Prize of Physiology or Medicine in 2021. If approved, resiniferatoxin may provide patients with long-lasting pain relief with a favourable safety profile.

... Grünenthal starts global clinical Phase III programme for resiniferatoxin (RTX)

2021 Disclosures

It is our fundamental responsibility to act with transparency and maintain the highest ethical standards in everything we do. As EFPIA members we are committed to publishing information about our collaboration with healthcare professionals (HCPs) and healthcare organisations (HCOs).
... Access the data on the 2021 Disclosures

Careers

Working at Grünenthal means experiencing the impact you can have on the results we achieve and the lives of the patients we serve.

Join forces.

Make an impact.

Innovate for a world free of pain.